Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Evinacumab→

Evinacumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1446419-85-7
Molecular formula
C6344H9784N1692O1988S46
Molecular weight
~143000 g/mol
Drug class
Angiopoietin-like protein 3 (ANGPTL3) inhibitorfully human monoclonal antibody
Mechanism of action
Binds ANGPTL3 and inhibits its interaction with lipoprotein lipase and endothelial lipase, increasing triglyceride-rich lipoprotein clearance and reducing LDL cholesterol through LDL-receptor-independent pathways.
Indications / reported uses
  • Adjunct to diet and other LDL-cholesterol-lowering therapies for patients aged 5 years and older with homozygous familial hypercholesterolaemia (HoFH); it is not indicated for general hypercholesterolaemia without HoFH

Sources: US DailyMed — EVKEEZA (evinacumab-dgnb) · FDA — Evinacumab approval for HoFH · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Evinacumab Environmental Risk Assessment (ERA) (the Evinacumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.